

## Efficacy Study Summary of the D6 STERIONZER<sup>™</sup> against surface SARS-CoV-2

Project	Filt Air Ltd. D6 Sterionizer™ Surface SARS-CoV-2		
Product	D6 STERIONIZER™ BIPOLAR NEEDLEPOINT IONIZER		
Laboratory Project #	1047		
Testing Facility	Innovative Bioanalysis, Inc		
Study Dates	04/06/2021 - 06/10/2021		
GLP Compliance	All internal SOPs and processes follow GCLP guidelines and recommendations.		
Test Substance	SARS-CoV-2 USA-CA1/2020		
Description	Filt Air Ltd. provided a D6 STERIONIZER <sup>™</sup> , a compact bipolar needlepoint-ionizing device designed to be integrated into an air movement system such as an HVAC duct system, air conditioner or humidifier. The in vitro study evaluates the efficacy of the D6 STERIONIZER <sup>™</sup> against SARS-CoV-2 on surfaces.		
Test Conditions	The study conducted two control tests and 3 viral challenges in a certified Biosafety hood inside a BSL-3 laboratory. The temperature during testing was approximately 73 ±2°F, with a relative humidity of 44%. Slide samples were collected after 0, 15 and 30-minute exposure to the operating device.		
Test Results	Active SARS-CoV-2 concentrations on the sample surfaces were reduced at the 15- minute and 30-minute time point. After 15 minutes of operation, the trial observed a decrease in the initial viral concentration of $6.32 \times 10^6$ to an average of $9.61 \times 10^5$ TCID50/ml and after 30 minutes to an average of $6.53 \times 10^3$ TCID50/ml.		
	Exposure Time	Reduction in %	]
	15 minutes	84.80	
	30 minutes	99.90	
Conclusion The Filt Air Ltd. D6 STERIONIZER <sup>™</sup> demonstrated the ability to reduce the concentration of the active pathogen SARS-CoV-2 on surfaces when exposed to a negative and positive ion concentration.			
Kevin Nable 5DE2797BAA78421			9/7/2021
Kevin Noble			Date

Laboratory Director, Innovative Bioanalysis, Inc.